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Artemisinin and its derivatives are the most rapidly acting and efficacious antimalarial drugs currently
available. Although resistance to these drugs has not been documented, there is growing concern about the
potential for resistance to develop. In this paper we report the selection of parasite resistance to artelinic acid
(AL) and artemisinin (QHS) in vitro and the molecular changes that occurred during the selection. Exposure
of three Plasmodium falciparum lines (W2, D6, and TM91C235) to AL resulted in decreases in parasite
susceptibilities to AL and QHS, as well as to mefloquine, quinine, halofantrine, and lumefantrine. The changes
in parasite susceptibility were accompanied by increases in the copy number, mRNA expression, and protein
expression of the pfmdr1 gene in the resistant progenies of W2 and TM91C235 parasites but not in those of D6
parasites. No changes were detected in the coding sequences of the pfmdr1, pfcrt, pfatp6, pftctp, and pfubcth genes
or in the expression levels of pfatp6 and pftctp. Our data demonstrate that P. falciparum lines have the capacity
to develop resistance to artemisinin derivatives in vitro and that this resistance is achieved by multiple
mechanisms, to include amplification and increased expression of pfmdr1, a mechanism that also confers
resistance to mefloquine. This observation is of practical importance, because artemisinin drugs are often used
in combination with mefloquine for the treatment of malaria.
Plasmodium falciparum parasites have developed resistance
to conventional antimalarial drugs by various means, including
alteration of the enzymes targeted by drugs (8, 23, 24, 32) and
mutation or amplification of the genes coding for proteins
involved in drug transport (13, 34, 35). One of these proteins,
P. falciparum multidrug resistance transporter 1 (PfMDR1), or
Pgh1, a P. falciparum homologue of mammalian P-glycopro-
tein (15, 45), has been implicated in resistance to several struc-
turally different antimalarial compounds. In early studies, ex-
posure of P. falciparum laboratory lines to mefloquine resulted
in amplification of the pfmdr1 gene (45), with concomitant
increases in resistance to mefloquine (MQ), quinine (QN), and
halofantrine (HF) (7, 30, 31, 45). Amplification of pfmdr1 was
also observed in field isolates from different geographical lo-
cations (4, 34, 35, 42). Increased pfmdr1 copy numbers (CN) in
field isolates were associated with higher inhibitory concentra-
tions (IC) of MQ, QN, HF, and artemisinin (QHS) in vitro (34,
46) and were linked to the failure of MQ monotherapy and
mefloquine-artesunate combination therapy in studies con-
ducted in Thailand and on the Thai-Cambodian border (2, 35).
Furthermore, direct evidence of the role of pfmdr1 in the
modulation of parasite susceptibility came from a report where
inactivation of 1 of 2 copies of pfmdr1 in the P. falciparum FCB
line led to moderate increases in susceptibilities to artemisinin
and arylaminoalcohol drugs (39).
In addition to gene amplification, several polymorphic posi-
tions in the pfmdr1 gene (N86Y, Y184F, S1034C, N1042D, and
D1246Y) have been identified in field isolates (14) and have
been shown to contribute to altered parasite responses to QN,
HF, MQ, chloroquine (CQ), and QHS in vitro (10, 28, 33, 36,
39). In particular, the last three mutations (S1034C, N1042D,
and D1246Y) are implicated in increased sensitivity to arte-
misinin over that of the “wild type” (with S, N, and D) (36).
Conversely, significant decreases in susceptibilities to QHS,
MQ, and HF are observed when the “wild-type” N at position
1042 is restored (39). These findings are consistent with the
early observation that the “wild-type” pfmdr1 allele (with N, Y,
S, N, and D) is associated with reduced susceptibilities of the
progeny of the genetic cross of the P. falciparum 3D7 and HB3
lines to MQ, HF, QHS, and artemether (10).
Although PfMDR1 is clearly implicated in the modulation
of parasite responses to antimalarial drugs, including artemisi-
nins, the mechanism of its action is largely unknown. A recent
study using heterologous expression of PfMDR1 in Xenopus
laevis oocytes demonstrated that some drugs, including HF,
QN, and CQ, are substrates for PfMDR1 (38). It is not clear
whether artemisinins interact with PfMDR1. Several proteins
have been shown to interact with artemisinin. The translation-
ally controlled tumor protein (TCTP) binds to radioactively
labeled dihydroartemisinin (5) and is overexpressed in rodent
Plasmodium yoelii parasite lines with decreased susceptibility
to artemisinin (44). Another protein that may interact with
artemisinins is the sarcoplasmic reticulum Ca2 ATPase 6
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(PfATP6); this enzyme, when expressed in Xenopus oocytes,
was specifically inhibited by artemisinin derivatives contain-
ing an endoperoxide bridge (11). In addition, the activity of
the enzyme was greatly influenced by the introduction of
several mutations (e.g., L263E) (43). Furthermore, analysis
of naturally occurring polymorphisms in PfATP6 in field
isolates from French Guiana suggested that a polymorphism
at codon 769 may be associated with reduced susceptibility
of these isolates to artemether in vitro (19). However, sub-
sequent reports failed to detect codon 263 or 769 polymor-
phisms in the field (12, 27, 48).
Although resistance to artemisinins has not been docu-
mented in the field, induction of artemisinin resistance in vitro
may help in the identification of molecular markers and drug
target sites as well as in designing strategies for combating
artemisinin resistance when it arises.
Several attempts have been made to develop resistance to
artemisinin derivatives in P. falciparum (18, 20, 47) in vitro.
Inselburg (18) induced resistance to artemisinin by using mu-
tagens, but these lines are no longer available for study. Other
attempts to select resistance with increasing drug pressure
have led to various endpoints. Jiang (20) produced a 3-fold
decrease in susceptibility to sodium artesunate (AS), but resis-
tance proved unstable. Yang et al. (47) achieved 8.9-fold re-
sistance to AS, although few data are available about the sta-
bility of the resistance selected or the methods used. A recent
study reported the development of stable resistance to QHS
and AS in the rodent parasite Plasmodium chabaudi chabaudi
(1). Linkage group analysis of the resistant progeny from the
same parental parasites identified two nonsynonymous muta-
tions occurring independently in the P. chabaudi putative ubiq-
uitin carboxyl-terminal hydrolase gene (pcubp1, or pcubcth):
V739F appeared after selection with artesunate, whereas
V770F occurred in progeny selected with CQ (17). No new
mutations in PcUBP1 were detected after further selection
with QHS. Attempts to develop stable resistance in the P.
falciparum NF54 and 7G8 parasite lines were unsuccessful;
parasites reverted to the sensitive phenotype after cryopreser-
vation (17).
Here we report the selection of resistance to artelinic acid
(AL) and to QHS and its derivatives in vitro in several P.
falciparum lines of different genetic backgrounds. We also in-
vestigated the possible mechanisms involved in the develop-
ment of resistance. We present evidence that pfmdr1 gene
amplification and expression are required in order for some,
but not all, parasites to withstand high concentrations of AL or
QHS in vitro.
MATERIALS AND METHODS
Parasite cultures. Two P. falciparum laboratory clones, W2 (Indochina) and
D6 (Sierra Leone), and a laboratory-adapted field isolate, TM91C235 (Thai-
land), were grown in vitro as previously described (41). Routine cultures were
maintained at 1 to 10% parasitemia in complete medium containing 10% heat-
inactivated human plasma and in O human erythrocytes. The three different
parasites were chosen in anticipation that differences in the genetic background
of the parasite may be important for the success of drug resistance selection.
Development of resistant parasite lines. Resistance to AL in P. falciparum
lines was induced essentially as described by Oduola et al. (29). The P. falciparum
W2, D6, and TM91C235 lines were cultured under increasing AL drug pressure
in stepwise increments over 28 months. The starting concentrations of AL were
0.5 ng/ml for the D6 and W2 clones and 10 ng/ml for TM91C235. The increments
used were 0.5, 1, 2, 4, 10, 20, 30, 40, 50, and 80 ng/ml, with an exposure time of
11 to 93 days at each increment. A routine drug exposure cycle began with the
addition of AL to asynchronous cultures at 4 to 8% parasitemia. The medium
was changed daily. Drug pressure was removed when parasite morphology de-
graded and growth was significantly affected. AL pressure was resumed when
parasite growth and morphology became normal. A parasite was considered
“adapted” when the recovery phase occurred within 2 to 4 days. Several times
during adaptation, parasites were frozen, and the process was resumed from
cryopreserved stocks. AL was used for the drug resistance selection studies
because, at the time these studies began, AL was a preclinical drug candidate in
the WRAIR program.
When W2 parasites became adapted to growth at 80 ng/ml of AL, these
parasites, designated W2AL80, were further subjected to QHS pressure, first at
20 ng/ml and then at 40 ng/ml. In parallel, the bulk culture of W2AL80 parasites
was cloned by limiting dilution, and one of the clones was subjected to increasing
AL and QHS pressures, up to concentrations of 200 ng/ml. During the adapta-
tion, samples of the cultures were collected and stored for further analysis.
Parasite susceptibility to the drugs was assayed by measuring the inhibition of
[3H]hypoxanthine uptake as described previously by Desjardins et al. (9). Data
were analyzed using GraphPad Prism software, version 5 (GraphPad Software,
Inc.). The concentrations of the drugs that inhibited parasite growth by 50% and
90% (IC50 and IC90) were obtained by nonlinear regression analysis of the
inhibition of uptake values and log-transformed concentration values.
Parasite DNA extraction. Genomic DNA was extracted from 1- to 2-ml ali-
quots of parasite cultures or cultures spotted onto filter paper by using the
NucleoSpin tissue kit (Macherey-Nagel, Germany). All of the DNA, RNA, and
protein assays were performed with untreated parasites (i.e., no drug pressure).
Sequencing of the pfmdr1, pfatp6, pftctp, pfcrt, and pfubcth genes. The pfmdr1
(PFE1150w), pfatp6 (PFA0310c), pftctp (PFE0545c), pfcrt (MAL7P1.27), and
pfubcth (PFA0220w) genes were amplified from genomic DNA using PCR. Gene
sequences were obtained from PlasmoDB (http://plasmodb.org/). The primers
used for PCR and sequencing of the genes, as well as the PCR conditions, are
shown in Table S1 in the supplemental material. It should be noted that 2
fragments of the pfmdr1 gene and 9 overlapping fragments of pfatp6 (3,965 bp)
were amplified and sequenced, while a full-length pfubcth gene (3,613 bp) was
amplified using Pfx DNA polymerase (Invitrogen, Carlsbad, CA) and sequenced.
To sequence the gene encoding the chloroquine resistance transporter (pfcrt),
total RNA was isolated, and cDNA was synthesized using the D7 primer (see
Table S1 in the supplemental material) as described in “Analysis of pfmdr1,
pfapt6, and pftctp transcription” below. The PCR product corresponding to the
mRNA of the gene was amplified using the E1 and D7 primers (see Table S1)
and sequenced. All PCR products were sequenced using the BigDye Terminator
cycle sequencing kit, version 3.1 (Applied Biosystems, Inc.), and sequences were
assembled and analyzed using the GAP4 program of the Staden package (40).
Determination of the pfmdr1 gene copy number by quantitative real-time PCR.
The copy number of the pfmdr1 gene was estimated by quantitative real-time
PCR in an Mx4000 multiplex quantitative PCR system (Stratagene) using a
SYBR green-based assay. The single-copy-number lactate dehydrogenase 1 gene
(pfldh1) was used as a reference (normalizer) gene for estimating the copy
number of pfmdr1 (the target). Primers MDR1-T1F and MDR1-T1R and prim-
ers LDH-T1F and LDHT1R (see Table S1 in the supplemental material) were
used to amplify fragments of the pfmdr1 and pfldh1 genes, respectively. PCRs
were performed in triplicate in 25 l PCR mixtures containing 1 Absolute
QPCR SYBR green mix (ABgene), 100 nM ROX (passive reference dye), 1 l
of DNA template, and 400 nM each primer for either pfmdr1 or pfldh1 ampli-
fication. Cycling conditions were as follows: 95°C for 15 min, followed by 40
cycles of 95°C for 30 s, 57°C for 1 min, and 72°C for 30 s. Fluorescence data were
collected at the end of each annealing and extension step three times and were
averaged. Following the amplification cycles, melting curve analysis was per-
formed to confirm that the correct products were synthesized. The text report,
containing the threshold cycle (CT) values for every well, was exported into the
Excel program (Microsoft Office XP) and analyzed.
The assay was optimized to achieve approximately equal amplification effi-
ciencies for the pfmdr1 and pfldh1 fragments within the experimental range of
DNA concentrations from 10 pg/l to 100 ng/l. Thus, the CT method (3)
could be used, and the pfmdr1 copy number (CN) was calculated as 2CT  SD.
CT was calculated as CTldh1  CTmdr1  CTldh1 cal  CTmdr1 cal. SD is a
standard deviation, calculated as S2mdr1  S2ldh1  S2cal, where Smdr1 and
Sldh1 are the standard deviations from the average CT calculated for three or four
replicates in the pfmdr1 and pfldh1 amplifications, and Scal is an average standard
deviation of the CT values for the calibrator. For every sample, the assay was
repeated at least three times. The results are presented as population mean CNs
and ranges with 95% confidence. Student’s t test was applied to evaluate differ-
ences between the CN values. The difference was considered significant if the
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probability that these values came from the same two underlying populations
that have the same mean was 0.05.
Real-time assays to quantify the pfatp6 and pftctp copy numbers in the parasite
genomes relative to that of the pfldh1 gene were also developed. Primer se-
quences and cycling conditions are shown in Table S1 in the supplemental
material. The assays were carried out and analyzed as described above.
Analysis of pfmdr1, pfapt6, and pftctp transcription. For the quantification of
the mRNA transcription of the pfmdr1, pfapt6, and pftctp genes, parasite cultures
were synchronized at the ring stage by repeated D-sorbitol-treatment (25) and
were allowed to grow for one cycle after the last treatment. Aliquots of parasite
cultures were taken every 6 to 8 h, starting from the early ring stage, over a
period of 48 h. Total RNA was extracted using NucleoSpin RNA II kits (Ma-
cherey-Nagel, Germany) with an additional DNase I (New England Biolabs)
treatment at 37°C for 	3 h, followed by a second round of RNA purification
using the same kit. To ensure that the total RNA was free from DNA contam-
ination, every preparation of RNA was tested by PCR prior to the first-strand
cDNA synthesis.
The first-strand cDNA synthesis was performed in a 20-l volume using
random hexamer primers (Promega) and Superscript III reverse transcriptase
(Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions.
Real-time PCR assays were designed to evaluate the levels of pfmdr1, pfatp6,
and pftctp RNA transcripts relative to those of the seryl-tRNA gene. Each 25-l
reaction mixture (Absolute QPCR SYBR green mixture; ABgene) contained 1
l of cDNA as a template. For the analysis of pfmdr1, pfatp6, and pftctp RNA
expression, the primers were identical to those used in the copy number assays
except for the seryl-tRNA (normalizer gene) primers (6). The primer sequences
and PCR conditions are shown in Table S1 in the supplemental material. Data
were analyzed as described above.
Southern blot hybridization. Parasite chromosomal DNA was prepared in
agarose blocks (21) and was digested with the BglI and SmaI enzymes. DNA
fragments were separated by pulsed-field gel electrophoresis (PFGE) in a 1%
SeaKem LE agarose gel and 0.5 Tris-borate-EDTA buffer (TBE) using a
CHEF-DR III system (Bio-Rad Laboratories, Hercules, CA) at 6 V/cm, with a
25- to 50-s pulse ramp for 16.5 h for BglI-digested DNA and a 70- to 130-s pulse
ramp for 22 h for SmaI digestion; then they were transferred to a nylon mem-
brane (Roche Diagnostics Pty, Ltd., Castle Hill, Australia) by capillary blotting.
Digoxigenin (DIG)-labeled pfmdr1- and fructose biphosphate aldolase
(PF14_0425)-specific probes were generated by PCR using the MDR01–MDR02
and AldoF-AldoR primer pairs, respectively (see Table S1 in the supplemental
material), and were purified using a PCR purification kit (Macherey-Nagel,
Germany).
Southern blot hybridizations were performed using EasyHyb hybridization
buffer (Roche Diagnostics Pty, Ltd., Castle Hill, Australia), alkaline phos-
phatase-conjugated anti-digoxigenin Fab fragments, CDP star substrate, and the
DIG Wash and Block buffer set (Roche Diagnostics Pty, Ltd., Castle Hill,
Australia) according to the manufacturer’s instructions.
Band intensity was quantified by ImageQuant software (Molecular Dynamics).
The ratio of the band intensity for resistant parasites (e.g., W2AL80) to that for
control parasites (e.g., W2) was calculated for the hybridization with the pfmdr1
probe and normalized to that with the aldolase probe.
Analysis of PfMDR1 protein expression by Western blotting. Synchronized
parasite cultures at 5 to 7% parasitemia were harvested at the late-trophozoite–
early-schizont stage, lysed in 0.1% saponin, and stored at 
80°C. For Western
blot analysis, parasite pellets containing approximately 106 parasites were resus-
pended in 1 phosphate-buffered saline (PBS) supplemented with protease
inhibitor cocktail (Roche Diagnostics, Australia) and were lysed by the addition
of sodium dodecyl sulfate (SDS) to a final concentration of 1%, followed by
incubation on ice for 10 to 15 min. Lysates were cleared by centrifugation at
13,000  g and 4°C for 10 min. Supernatants were mixed with 6 sample loading
buffer (containing 10% SDS, 100 mM dithiothreitol [DTT], Tris-HCl [pH 6.8],
glycerol, and bromphenol blue) and were boiled prior to being loaded onto a 7%
SDS-polyacrylamide gel electrophoresis (PAGE) gel for subsequent Western
blot analysis.
For PfMDR1 detection, a 1/50 dilution of affinity-purified polyclonal sera
against the C terminus of Pgh1 (1435; kindly provided by A. Cowman) was
used. Monoclonal anti-RAP2 antibodies (Ab) (6C1; kindly provided by M. Hog-
arth) were used (at a 1:2,000 dilution) as an internal control. Horseradish per-
oxidase (HRP)-conjugated anti-rabbit IgG (dilution, 1:5,000 or 1:10,000) was
used to detect PfMDR1-bound Ab, and HRP-conjugated anti-mouse IgG (1:
5,000) was used for RAP2 detection with an ECL detection kit (Amersham,
United Kingdom). Band intensity was quantified using ImageQuant software
(Molecular Dynamics).
RESULTS
Development of P. falciparum lines resistant to artelinic acid
and other artemisinin derivatives in vitro. Before drug expo-
sure, the IC90 values of AL for the parental parasite lines W2,
D6, and TM91C235 ranged from 7.45 to 22.99 nM (Table 1).
As the parasites became adapted to gradually increased con-
centrations of AL, their susceptibilities to AL and other anti-
malarial drugs changed markedly (Fig. 1). All three lines be-
came less susceptible to AL, QHS, dihydroartemisinin (DHA),
and MQ (Fig. 1) but more susceptible to CQ. Three different
adaptation patterns were observed. For the W2 clone, marked
reductions in sensitivities to AL and QHS were observed when
parasites became adapted to 40-ng/ml AL drug pressure, and
the same trend continued up to the 80-ng/ml AL level (Fig.
1A). The susceptibility of the TM91C235 line to AL (Fig. 1B)
decreased and reached a plateau following exposure to 30
ng/ml, while the susceptibility of D6 decreased immediately
after exposure to 30 ng/ml of AL and did not decrease further
after exposure to higher drug concentrations (Fig. 1C). Inter-
estingly, in the absence of drug pressure, the selected progeny
progressed normally through the erythrocytic stages of the life
cycle, with no substantial differences in growth from the pa-
rental lines.
Acquisition of resistant phenotypes is independent of poly-
morphism in the pfcrt, pfmdr1, pfatp6, and pfubcth genes. The
key polymorphic regions of the pfmdr1 gene, containing codons
86, 184, 1034, 1042, and 1246, were sequenced in the parental and
resistant progenies. The amino acids at these positions are shown
in Table 2. Mutations N86Y and Y184F were observed in the
parental W2 and TM91C235 parasite lines, respectively, while D6
parasites had “wild-type” PfMDR1. No changes in the gene cod-
ing sequences were detected in the resistant progenies D6AL80,
TM91C235AL80, W2AL200, W2QHS200, and W2AS80 (Ta-
ble 2).
The entire genes coding for TCTP, PfATP6, and PfUCTH,
including introns of the two latter genes, were sequenced in the
parental parasites and their resistant progenies D6AL80,
TM91C235AL80, W2AL200, W2QHS200, and W2AS80. In all
parental and resistant lines, the sequence of the pftctp gene was
identical to that of isolate 3D7 (PlasmoDB). The pfatp6 DNA
sequences in the D6, W2, and TM91C235 parental lines were
identical to that of isolate K1 (GenBank accession no. X71765)
with the following exceptions. A nucleotide change from G to
TABLE 1. In vitro susceptibilities of Plasmodium falciparum lines to
artelinic acid
Parasite line
Mean IC (nM)  SDa
50% 90%
W2 4.73  0.19 7.45  0.40
W2AL50 23.30  3.95 51.31  1.31
W2AL80 22.75  5.37 56.80  5.44
D6 9.81  1.41 21.83  3.04
D6AL50 34.00  3.14 81.26  8.67
D6AL80 23.64  3.71 75.89  2.60
TM91C235 11.08  1.68 22.99  2.60
TM91C235AL50 33.72  1.64 53.51  1.12
TM91C235AL80 24.55  4.13 75.89  6.8
a n, 3.
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A at position 3376 (numbering as in GenBank accession no.
X71765) in the pfatp6 genes of the parental TM91C235 and D6
parasites, as well as in their respective resistant progenies,
resulted in an amino acid change from D to G in the region
between the M6 and M7 transmembrane domains (22). In
addition, a different number of microsatellite (AT) repeats was
observed in the 2nd intron sequence of the parental lines. The
previously reported polymorphisms (19) at position 414, cor-
responding to codon 89I or codon 769, were not observed in
any of the sequences. Importantly, no changes in the pfatp6
sequence were observed between the parental lines and their
corresponding resistant progenies.
No mutations corresponding to those in the putative pcubcth
gene found in artemisinin-resistant P. chabaudi parasites (V739F
and V770F [17]) were detected in the pfubcth genes amplified
from these parasite lines. Differences in sequence between para-
sites of different origins were detected: the repetitive region be-
tween codons 670 and 737 (based on the PfUBCTH sequence of
3D7) differed in the number and types of repeat units (see Table
S2 in the supplemental material). However, there was no differ-
ence in sequences between the parent and progenies of the same
lineage (see Table S2). The part of the pfcrt gene coding sequence
(excluding introns) corresponding to codons 36 to 380 was also
sequenced. No differences were observed in the DNA sequences
of the pfcrt gene between the W2, D6, and TM91C235 parental
parasites and their respective progeny.
FIG. 1. Changes in the index of resistance (ratio of the IC50 for the resistant progeny to the IC50 for the parental line) to various drugs during
the adaptation of the Plasmodium falciparum lines W2 (A), TM91C235 (B), and D6 (C) to artelinic acid (AL).
TABLE 2. pfmdr1 allelic types in parental and resistant
Plasmodium falciparum lines
Parasite line
Amino acid at position:
86 184 1034 1042 1246
D6 N Y S N D
D6AL80 N Y S N D
TM91C235 N F S N D
TM91C235AL80 N F S N D
W2 Y Y S N D
W2AL200 Y Y S N D
W2QHS200 Y Y S N D
W2AS80 Y Y S N D
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Amplification of the pfmdr1 gene is associated with the ac-
quisition of the resistant phenotype, and the copy number is
proportionate to the level of resistance in W2 and TM91C235,
but not in the D6 line. The copy number of pfmdr1 was as-
sessed in samples taken from parental lines and their corre-
sponding progeny during adaptation to AL and QHS by using
quantitative real-time PCR. The parental parasite W2 con-
tained a single copy of the pfmdr1 gene (CN, 0.93; 95% con-
fidence interval [95% CI], 0.83 to 1.04). A single copy of
pfmdr1 was also detected in samples taken from W2 cultures
exposed to 10 to 30 ng/ml of AL (CN, 1.02; 95% CI, 0.99 to
1.06) (Fig. 2). However, a change from 1 to 3 copies (CN, 3.01;
95% CI, 2.83 to 3.19 [P, 0.001]) was observed when the AL
concentration was increased to 50 ng/ml. A further increase in
the AL drug pressure to 80 ng/ml did not result in any detect-
able change in the pfmdr1 copy number (P, 0.53), since
W2AL80 parasites appeared to retain 3 copies of pfmdr1 per
genome (CN, 3.15; 95% CI, 3.01 to 3.30) (Fig. 2).
A bulk culture of W2AL80 parasites was cloned by limiting
dilution, and one of the clones with 3 copies of the pfmdr1 gene
(CN, 2.99; 95% CI, 2.74 to 3.26) was used in further experi-
ments. No detectable increase (P, 0.44) in the pfmdr1 copy
number (CN, 2.94; 95% CI, 2.77 to 3.12) was observed when
the AL concentration reached 120 ng/ml. However, at 200
ng/ml, the pfmdr1 copy number rose to 3.65 (95% CI, 3.19 to
4.17) (Fig. 2). Still, the difference in CN between W2AL120
and W2AL200 was not significant (P, 0.07).
During the study, W2AL80 parasites (bulk culture) were
also exposed to QHS pressure at increasing concentrations,
starting with 20 ng/ml and reaching 200 ng/ml. The adaptation
of parasites to 40 ng/ml of QHS was associated with a decrease
in the pfmdr1 copy number from 3 to 2 (CN, 2.2; 95% CI, 2.1
to 2.4) (Fig. 2). These parasites, referred to as W2QHS40, were
cloned by limiting dilution. A clone carrying 2 copies of pfmdr1
was subjected to further QHS pressure, yielding parasites able
to withstand a QHS concentration of 200 ng/ml. The pfmdr1
copy number remained at 	2 (CN, 1.99; 95% CI, 1.94 to 2.03)
(Fig. 2).
The adaptation of TM91C235 parasites to AL also resulted
in an increase in the pfmdr1 copy number (Fig. 2). Although
the uncloned parental line had a single copy of pfmdr1 at the
start of the selection studies, TM91C235 was isolated from a
patient with mefloquine treatment failure and originally had
multiple copies of pfmdr1 (unpublished results). During long-
term culture in the lab, the line had reverted to having only 1
copy. Exposure of these parasites to AL pressure resulted in an
immediate increase in the pfmdr1 copy number from 1 to 2
(CN, 2.05; 95% CI, 1.93 to 2.08) at 10 to 50 ng/ml of AL and
a further increase to 3 copies (CN, 2.94; 95% CI, 2.6 to 3.2)
when the AL concentration was increased from 50 to 80 ng/ml.
The difference in the CN was significant (P, 0.001).
The D6 parental parasites contained 1 copy of the pfmdr1
gene (CN, 0.97; 95% CI, 0.90 to 1.15). However, when these
parasites had adapted to AL pressure (up to 80 ng/ml), the
pfmdr1 copy number remained stable, with 1 copy detected in
all samples taken from resistant D6 progeny during the course
of the adaptation (P, 0.61) (Fig. 2).
A Southern blot hybridization technique was employed to
analyze the chromosomal rearrangements, as well as to con-
firm the changes in the pfmdr1 copy number, in the resistant
FIG. 2. pfmdr1 copy numbers in parental parasites and resistant progenies.
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progenies. The SmaI DNA fragment containing pfmdr1 in
W2AL80 parasites is approximately 300 kb longer than that in
W2 parasites. The intensity of this band was	3.6 times greater
than that in W2 parasites after the DNA loading was normal-
ized to the hybridization signal obtained for the aldolase gene
probe, indicating an amplification of the segment of chromo-
some 5 containing the pfmdr1 gene (Fig. 3). A faint band was
also observed in the SmaI digest of the W2AL80 parasites,
indicating the presence of a minor population of parasites with
a smaller version of chromosome 5 containing pfmdr1.
FIG. 3. Southern blot hybridization of P. falciparum chromosomes digested with SmaI (left) and BglI (right) and hybridized with probes derived
from the pfmdr1 (A) and aldolase (B) genes.
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It is apparent from the blots that the W2QHS40 parasite
progeny consisted of two parasite populations: those with a
larger SmaI fragment, equal in size to that in W2AL80 para-
sites, and those with a smaller version of the SmaI fragment of
the chromosome hybridizing to the pfmdr1 probe (Fig. 3). The
intensities of these bands were 1.4- and 2-fold (for the upper
and lower bands, respectively) greater than those for W2 par-
asites after correction for equal loading, indicating the pres-
ence of multiple copies of the pfmdr1 gene. In contrast to
SmaI, the BglI enzyme cuts between the amplicons, resulting in
an apparently single band, similar in size to that for 3D7 par-
asites but with increased intensity. From the 3D7 genome
sequence data (www.plasmodb.org/), the size of the BglI frag-
ment containing the pfmdr1 gene is 111,139 bp. In the 3D7
genome, this fragment is located between bp 903371 and
1014509 of chromosome 5 (www.plasmodb.org) and contains
21 genes; pfmdr1 is in the middle, at bp 957885 to 962144.
Thus, it appears that chromosome 5 in W2AL80 or W2QHS40
parasites contains three- or two-times-amplified segments of
	111 kb, respectively.
The size of the SmaI fragment containing the pfmdr1 gene in
TM91C235AL80 parasites did not differ significantly from that
for either TM91C235, W2, or 3D7 parasites. Based on the
results of BglI blotting, the pfmdr1-containing BglI fragment is
estimated to be 	10 to 20 kb larger than that in the parental
TM91C235 and 3D7 parasites. The intensity of the pfmdr1
gene-containing band is 2-fold higher for SmaI-digested
TM91C235AL80 DNA than for SmaI-digested TM91C235
DNA. Thus, the size of the amplicon containing the pfmdr1
gene in TM91C235AL80 parasites is different from that in
W2AL80 parasites. No rearrangements were detected around
the pfmdr1 gene in D6AL80 parasites relative to D6 parasites.
and the bands were of similar intensities (calculated ratio, 1.3).
pfmdr1 mRNA expression and PfMDR1 protein expression
are proportionate to the copy number of the pfmdr1 gene. The
RNA transcription levels of the pfmdr1 gene were assessed
using a quantitative real-time reverse transcription-PCR (RT-
PCR) assay. The transcription of the pfmdr1 gene was mea-
sured relative to that of the seryl-tRNA synthetase gene (PF07-
0073) every 6 to 8 h, starting with rings (0 h) and ending with
mature schizonts. When these values for the parental parasites
and their resistant progeny were compared (Fig. 4), pfmdr1
transcription was found to be 3- to 5-fold higher in W2AL80
parasites and 2.2- to 2.4-fold higher in W2QHS40 parasites
than in the parental W2 parasites. A similar increase of 2.1-
fold in transcription was observed for TM91C235AL80 para-
sites relative to their parental parasites. No difference in
pfmdr1 transcription was observed between D6AL80 parasites
and the parental D6 parasites (Fig. 4).
Western blot analysis of PfMDR1 protein expression (Fig. 5)
revealed that the amounts of the MDR1 protein detected in
the W2AL80, W2QHS40, and TM91C235AL80 lines were 3.1-,
2.2-, and 3.8-fold higher than those in their corresponding
parental lines. The amount of MDR1 protein in the D6AL80
parasites was 2.5-fold higher than that in D6 parasites (Fig. 5).
pfatp6 and tctp transcription in parental and resistant par-
asite lines. The transcription levels of two other genes of in-
terest, pfatp6 and pftctp, at the different time points of the
parasite life cycle were also analyzed using real-time PCR
assays. No significant changes in the transcription profiles of
these genes between the resistant parasites and their respective
parental parasites were detected (data not shown).
DISCUSSION
The potential emergence of artemisinin resistance is a major
concern given the global reliance on artemisinin combination
therapy as the major control measure. In this study, resistance
to artemisinin derivatives has been induced in several clones
and lines of P. falciparum in vitro. This in vitro resistance to AL
is different from resistance to other conventional antimalarial
drugs, such as CQ, in that AL-resistant parasites could not
grow permanently under the AL pressure. It is confirmed by
the ability of the parasites to survive and grow with increasing
concentrations of artemisinin derivatives for many generations
and by major increases in the IC50. The discontinuous drug
pressure selection scheme may have been the key to success in
selecting the resistant lines. Upon adaptation, parasites were
able to tolerate as much as 200 ng/ml of QHS or AL and grew
rapidly under the pressure for many asexual cycles. These
concentrations are comparable to those achieved in plasma
obtained from malaria patients treated with QHS. Further-
more, when in vitro resistance to one artemisinin derivative
developed, there was a significant degree of cross-resistance to
various other artemisinin derivatives, including AL, AS, and
DHA, as well as to MQ. These artemisinin-resistant parasites
provide a unique resource and opportunity for the study of the
artemisinin resistance mechanism(s) and modes of action. For
FIG. 4. Transcription of the pfmdr1 gene in the W2, W2AL80, W2QHS40, TM91C235, TM91C235AL80, D6, and D6AL80 lines of P. fal-
ciparum.
VOL. 54, 2010 pfmdr1 AND ARTEMISININ RESISTANCE IN P. FALCIPARUM 2461
 o
n
 N
ovem
ber 4, 2015 by University of Queensland Library
http://aac.asm
.org/
D
ow
nloaded from
 
example, the drug-selected lines were used to demonstrate that
deamplification of the pfmdr1 amplicon only partially restores
susceptibility to AL (6a).
In two of the three parasite lines (W2 and TM91C235) used
in the present study, the decrease in parasite susceptibility to
the drugs was associated with a concomitant increase in the
pfmdr1 copy number and a proportional increase in the levels
of pfmdr1 transcription and protein expression. These findings
indicate a clear involvement of pfmdr1 in the AL- and QHS-
resistant phenotypes. Notably, a switch from AL to QHS re-
sulted in a shift from a parasite population with 3 copies of
pfmdr1 to a parasite population that predominantly had 2 cop-
ies of the pfmdr1 gene. This indicates that the parasite popu-
lation with 2 pfmdr1 copies had an advantage over that with 3
copies under QHS pressure. Whether this is due to a difference
in the mode of action between AL and QHS or to a difference
in the mechanisms of resistance to the two artemisinin deriv-
atives remains to be investigated.
The amplification of the pfmdr1 gene was shown to be a
random, independent event (42). The size differences in the
pfmdr1 amplicons observed for the TM91C235 and W2 re-
sistant progenies in this study provide further support for
this observation. These rearrangements involve large re-
gions (20 to 110 kb) of the chromosomes, with amplification
of as many as 19 genes, including the pfmdr1 gene (Chen et
al., submitted). None of these genes except pfmdr1 had a
known modulation effect on antimalarial drugs. A recent
study by Gonzales et al. identified this region of chromo-
some 5 as one of the most prominent expression regulatory
loci, which influenced the expression of 269 genes located on
other chromosomes (16). Although we could not rule out
the possibility that the amplification of genes other than
pfmdr1 may play a part in the development of resistance, our
results, taken together with those of Sidhu et al. (39), sug-
gest that overexpression of pfmdr1 plays the most significant
role in the drug susceptibility changes compared to the
overall effect of the amplification of other genes contained
within the pfmdr1 amplicon.
While our data demonstrate the involvement of pfmdr1 ex-
pression in the resistance phenotype in two of the three para-
site lines, it is also apparent that amplification of pfmdr1 is not
the only possible mechanism of sustaining resistance, since no
pfmdr1 amplification was observed in D6 parasites exposed to
similar drug levels. The reason for this difference is not clear,
though it does suggest that amplification of pfmdr1 is not a
general stress response for P. falciparum. D6 is the only pa-
rental parasite line that harbors a “wild-type” pfmdr1 allele,
while the other two parental parasite lines carry “mutant-type”
pfmdr1 alleles. The “wild-type” pfmdr1 allele is intrinsically
associated with decreased susceptibilities to MQ, HF, and the
artemisinin drugs. Whether a “wild-type” pfmdr1 allele is as-
sociated with a different resistance mechanism remains to be
investigated. D6 also is the only line from Africa used in this
study. Perhaps there is a genetic basis for pfmdr1 amplification,
since most reports of this CN variant, both in lab-pressured
mutants and in field isolates, are from Asia.
Although it is clear that pfmdr1 plays a significant role in
resistance, some studies also demonstrated that changes in
susceptibility to MQ or HF could be achieved without changes
in the expression level or allelic type of pfmdr1 (26, 37), sug-
gesting a possible involvement of other genes and/or mecha-
nisms of sustaining resistance in these parasites, including tran-
sient changes in gene expression, which may account for the
loss of resistance after cryopreservation of parasites observed
FIG. 5. MDR1 protein expression in resistant and parental Plasmodium falciparum lines. Western blot hybridization was performed with
anti-Pgh1 (1435; left side in panels A and B) and anti-RAP2 (6C1; right side in panels A and B) antibodies.
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by Hunt et al. (17). Importantly, the parasites produced in this
study retain the resistance phenotype, as defined by the ability
to survive exposure to high drug concentrations, even after
cryopreservation.
Notably, the IC90 values of AL and QHS for all three par-
asite lines after adaptation were lower than the concentrations
the parasites could endure in vitro. Moreover, although para-
sites became adapted to 80 ng of AL/ml, their IC50 and IC90
values were not different from those obtained for AL50 para-
sites. This suggests that the artemisinin resistance phenotype
may be underestimated by the commonly used in vitro resis-
tance measurements, such as IC50 and IC90, obtained by the
standard 48- to 72-h drug susceptibility assay. These data also
suggest that the standard drug assays may not be appropriate
for assessment of the artemisinin resistance phenotype in the
field.
Several recent publications have suggested that mutations
in pfatp6, encoding the sarco-endoplasmic reticulum Ca2
ATPase, are associated with resistance to artemisinin com-
pounds. In particular, the S769N mutation, found in the pfatp6
genes of field isolates collected in French Guiana, was associ-
ated with higher IC50 of artemether in vitro (19). In our study,
no amino acid changes in the pfatp6 product, and no changes
in its expression, were detected. No changes in the expression
or DNA sequence of the pftctp1 gene were detected in the P.
falciparum parasite lines used in our study, in contrast to a
previously reported increase in tctp expression in artemisinin-
resistant rodent parasites (44), but in agreement with findings
reported by Hunt et al. (17).
The identification of putative molecular markers of resis-
tance to artemisinin drugs is of immense importance. The
development of artemisinin-resistant parasites in vitro provides
a powerful framework for studies that need not focus on can-
didate genes. Our data suggest that among all the proposed
candidate genes, only pfmdr1 amplification is associated with
the artemisinin resistance phenotype, yet clearly this is not the
most critical determinant for resistance to artemisinin. In the
drug-selected lines, mutations in the candidate resistance
genes have no role in the resistance phenotype, yet the possi-
bility of single nucleotide polymorphisms (SNPs) in other
transporters or novel CN variants cannot be ruled out. There-
fore, the selected lines are being used for whole-genome se-
quencing to identify CN variants or SNPs associated with the
resistance phenotype.
At present, artemisinin combinations are the most effective
antimalarial drugs. However, our data clearly suggest that par-
asites can tolerate increasing concentrations of artemisinin
drugs by amplifying the pfmdr1 gene. Since amplification of
pfmdr1 is also a mechanism of resistance to MQ, consideration
should be given when combinations such as artesunate-meflo-
quine are used in areas with high levels of MQ resistance.
Finally, it is clear that pfmdr1 amplification is not the central
determinant of artemisinin resistance, but it is possibly an
important event that may enhance artemisinin resistance, es-
pecially in Southeast Asia. The artemisinin-resistant mutants
produced in this study will be an important resource in the
search for molecular markers of artemisinin resistance.
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